The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The Trump administration will not permit Medicare to pay for obesity drugs directly, declining Friday to finalize a Biden-era ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...